COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
    13.
    发明公开
    COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS 审中-公开
    化合物和组合物作为c-KIT激酶抑制剂

    公开(公告)号:EP2751102A1

    公开(公告)日:2014-07-09

    申请号:EP12756879.8

    申请日:2012-08-28

    申请人: IRM LLC

    CPC分类号: C07D471/04

    摘要: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFR&bgr;) kinases.

    摘要翻译: 本发明提供了用作蛋白激酶抑制剂的式(I)和(II)的化合物及其药物组合物,以及使用这些化合物治疗,改善或预防与异常或失调的激酶活性相关的病症的方法。 在一些实施方案中,本发明提供了使用此类化合物来治疗,改善或预防涉及c-kit或c-kit和PDGFR(PDGFRα,PDGFRβ)激酶的异常活化的疾病或病症的方法。

    2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
    16.
    发明公开
    2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS 有权
    作为激酶抑制剂的2-杂芳基氨基 - 嘧啶衍生物

    公开(公告)号:EP2190836A1

    公开(公告)日:2010-06-02

    申请号:EP08798064.5

    申请日:2008-08-18

    申请人: IRM LLC

    摘要: The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-raf or b-raf kinases.

    摘要翻译: 本发明提供了用作蛋白激酶抑制剂的式(I)化合物及其药物组合物,以及使用这些化合物治疗,改善或预防与异常或失调的激酶活性相关的病症的方法。 在一些实施方案中,本发明提供了使用这些化合物来治疗,改善或预防涉及c-kit,PDGFRα,PDGFRβ,CSF1R,Abl,BCR-Abl,CSK,JNK1,JNK2,p38等异常活化的疾病或病症的方法。 p70S6K,TGFβ,SRC,EGFR,trkB,FGFR3,Fes,Lck,Syk,RAF,MKK4,MKK6,SAPK2β,BRK,Fms,KDR,c-raf或b-raf激酶。